ASCO 2023 Kidney Cancer - Results from #20

Viewing 21-32 of 32 articles

ASCO 2023: Health-Related Quality of Life Measures in RCC: Patient-Reported Relevance of Items of the FKSI-19, EORTC QLQ-C30, and EQ-5D

ASCO 2023: Adjuvant Everolimus in Patients with Localized Non-Clear Cell Renal Cell Carcinoma: Subgroup Analysis from the EVEREST Trial

ASCO 2023: Nivolumab plus Cabozantinib in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial

ASCO 2023: Core Biopsy Accuracy and Safety of Biopsy and Preoperative Immunotherapy in Predicting Histological Subtype and Nuclear Grade in ECOG-ACRIN EA8143 Perioperative Nivolumab Versus Observation in Patients with Kidney Cancer Undergoing Nephrectomy

ASCO 2023: Characterizing Progression to Subsequent Lines of Therapy in Metastatic Renal Cell Carcinoma After Nivolumab plus Ipilimumab (Nivo+Ipi): Results from the IMDC

ASCO 2023: Phase 2 Study of Batiraxcept as Monotherapy, in Combination with Cabozantinib, and in Combination with Cabozantinib and Nivolumab in Patients with Advanced Clear Cell Renal Cell Carcinoma

ASCO 2023: Head-to-Head Effectiveness and Safety of Pembrolizumab plus Axitinib vs. Nivolumab plus Ipilimumab in Metastatic Renal Cell Carcinoma in the United States

ASCO 2023: CASSIOPE: A Prospective Noninterventional Study of Cabozantinib Treatment Following Prior Vascular Endothelial Growth Factor - Targeted Therapy in Patients with Advanced Renal Cell Carcinoma

ASCO 2023: Health-Related Quality of Life (HRQoL) of Risk-Based Patient Subgroups with Advanced Renal Cell Cancer (aRCC) Treated with Nivolumab plus Cabozantinib vs Sunitinib in the CheckMate 9ER Trial

ASCO 2023: A Phase I/II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination with Atezolizumab and Bevacizumab in Patients with Renal Cell Carcinoma

ASCO 2023: Biomarker-Driven Prospective Clinical Trial in Renal Cell Carcinoma: Developing Machine Learning Models to Allocate Patients to Treatment Arms Using RNA Sequencing

ASCO 2023: Determinants of Resistance to Nivolumab Monotherapy Investigated Through Genomic and Transcriptomic Analysis of Renal Cell Carcinoma Tumors from the HCRN GU16-260 Study

1
2